2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1345

Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1201

Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1597

Assessing Long-term Poor Outcomes in Systemic Lupus Erythematosus Patients with Acute Coronary Syndromes

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1079

Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1596

Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1565

Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1631

Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1663

Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1394

Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1386

Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1433

Association Between Seropositivity and Discontinuation of Tumor Necrosis Factor Inhibitors Due to Insufficient Response in Rheumatoid Arthritis

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1606

Association of African- American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1401

Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 960

Autoantibodies in Rheumatoid Arthritis Target Citrulline-Containing and Native Epitopes from Conformationally Disordered Regions of Proteins

B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1323

Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma

Osteoarthritis – Clinical Poster I

«Previous Page
1
…
3
4
5
6
7
…
65
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].